Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 15/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.39 |
| ▸ | DLK1 | P80370 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108634 | 0.89 | MAP3K12 (0.44) | MAP3K12CHRNA7KCNH2GRIN2DGRIN3B | |
| SCHEMBL25685954 | 0.79 | MAP3K12 (0.43) | MAP3K12CHRNA7KCNH2MAP3K13DLK1 | |
| SCHEMBL15743911 | 0.79 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL15743920 | 0.79 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL26151691 | 0.79 | MAP3K12 (0.40) | MAP3K12CHRNA7KCNH2 | |
| SCHEMBL25147712 | 0.79 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL15743901 | 0.79 | CHRNA7 (0.66) | CHRNA7KCNH2 | |
| SCHEMBL25678579 | 0.77 | MAP3K12 (0.42) | MAP3K12CHRNA7KCNH2MAP3K13 | |
| SCHEMBL1108656 | 0.76 | CHRNB2 (0.58) | — | |
| SCHEMBL13103767 | 0.76 | CHRNB2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | MAP3K12 996/4885CHRNA7 143/4885KCNH2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.